Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discounts will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Relay Therapeutics, which aims to take down difficult cancer drug targets by combining computational methods with emerging lab tools, has raised a whopping $400 million in its third formal financing round. The privately held company says it is the biggest series C in biotech industry history. Relay plans to use the money to build its computational tools, expand its workforce from 70 people to 100, and put compounds in the clinic.
This article has been sent to the following recipient: